Skip to main content

Multicolumn Countercurrent Solvent Gradient Purification Process To Be Discussed By YMC at the World Biopharma Forum 2022

History shows that uptake of innovation is metered in the biopharma industry, but if the invention has checked all the “user need” boxes, its acceptance has an inflection point. This inflection point, when graphed, resembles a hockey stick (hopefully pointing skyward).

For the purification of peptides and oligonucleotides, the process innovation of MCSGP* has reached that inflection point in 2021, and all indications are that the trajectory of MCSGP in 2022 will see even further large-scale production implementations. The burgeoning interest in oligonucleotide-based therapies by start-ups as well as large global biopharma’s has simultaneously revealed the vast potential therapeutic and curative applications for these molecules but also the need for technologies that solve the yield vs. purity dilemma in manufacturing cost at production scale.

*Multicolumn Countercurrent Solvent Gradient Purification process (MCSGP) is quickly being adopted by large-scale CMOs as a means to accelerate the cost-effective production of both oligo and peptide therapies. While heralded as a means to vastly increase yields at the target purity, as the end-users have modeled the incorporation of MCSGP into their production plants. They have been surprised at the true impact of this technology on cost reduction not only in the purification steps but also significant reductions in upstream synthesis and downstream processes.

In this year’s World Biopharma Forum 2022, we will be reporting on the present scale of incorporation as well as the MCSGP benefits tallied by its users, including:

– Decrease in synthesis batches required (or increase in capacity)
– Reduction in QC analysis and handling
– Potential for reduction in solvent consumption
– A peek into the next iteration of MCSGP that increases both yield and purity.

YMC: Providing Cost-Effective Solutions to Purification Processes

YMC is dedicated to offering tangible solutions to the problems faced by CMOs while implementing purification processes. We consistently strive to improve the tools and resources needed to overcome the complexities of purification in both small and large-scale manufacturing facilities.

To learn more about cost-effective solutions to the purification process, reach out to YMC. If you’re searching for columns and accessories or want more information on chromatography hydrophobic interactions, contact our team today. We look forward to hearing from you.

Posted on March 23, 2022.

Related Posts

YMC’s BioPro is a Reliable Tool for Analyzing PEGylated Proteins

January 15, 2022

YMC’s BioPro is a Reliable Tool for Analyzing PEGylated Proteins

Ligand® Pharmaceuticals Inc. had an excellent success utilizing YMC’s BioProIEX to analyze PEGylated protein charge variants reproducibly. They developed a characterization method for PEGylated biotherapeutic proteins that can provide increased information without compromising peak shape and resolution and wanted to
We’re Making Moves To Serve You Better

July 12, 2021

We’re Making Moves To Serve You Better

YMC America just completed the combination and expansion of our US operations at our YMC campus in Devens, MA. This puts our columns and stationary phase team under the same roof (actually, several roofs) with the research, design, and manufacturing
YMC America Business Operations to Relocate to Devens, MA

January 6, 2021

YMC America Business Operations to Relocate to Devens, MA

YMC America business operations will relocate to Devens, MA, to add resources, space, and improved access to the epicenter of the global bio/pharma industry.

Designed and developed by